Research
Cellular
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) demonstrate notable cardiovascular benefits beyond glucose regulation in patients with coronary artery disease (CAD).
Practitioners should consider SGLT2i and GLP-1 RAs for cardiovascular protection in CAD patients.
StrongSupportsmedium confidence
pharmacologic agents originally developed for glycemic control have demonstrated notable cardiovascular benefits beyond glucose regulation.
Why this rating
The abstract suggests a review of clinical data supporting these claims.
Source
Cardiovascular Protection in Coronary Artery Disease: Mechanistic and Clinical Insights into SGLT2 Inhibitors and GLP-1 Receptor Agonists
Nicola Cosentino et al. · Pharmaceuticals · 2025
DOI 10.3390/ph18081202
reviewCited 5×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- The interaction between hyperglycemia, endothelial dysfunction, inflammation, and thrombosis contributes to the progression of coronary artery disease (CAD) and its acute complications.Strong
- There has been a shift in the therapeutic approach to coronary artery disease (CAD) in patients with Type 2 Diabetes Mellitus (T2DM).Strong
Related findings · Cellular
- Athletes aiming to reduce fat mass and preserve FFM should consume protein intakes in the range of ∼1.8-2.7 g kg(-1) d(-1).Strong
- A minimum daily protein intake of ≥1.6 g/kg is necessary to observe significant improvements in muscle mass from whey protein supplementation.Strong
- Most athletes ideally need 1.2 to 2.0 grams/kg of body weight/day of protein, preferably split across 3-4 meals.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →